Stryker Co. (NYSE:SYK) Stock Position Raised by Gotham Asset Management LLC

Gotham Asset Management LLC raised its position in Stryker Co. (NYSE:SYK - Free Report) by 139.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,251 shares of the medical technology company's stock after buying an additional 2,478 shares during the quarter. Gotham Asset Management LLC's holdings in Stryker were worth $1,531,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Elefante Mark B acquired a new stake in shares of Stryker in the 4th quarter worth $337,000. Chicago Capital LLC boosted its position in shares of Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares in the last quarter. Zhang Financial LLC raised its position in Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after acquiring an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA lifted its holdings in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Metis Global Partners LLC grew its position in shares of Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after purchasing an additional 1,561 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus boosted their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price objective on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Roth Mkm increased their target price on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, Citigroup restated a "buy" rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $427.05.

Stryker Stock Down 1.4%

Stryker stock traded down $5.39 during midday trading on Tuesday, hitting $389.30. 1,047,447 shares of the stock were exchanged, compared to its average volume of 1,346,270. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a 50 day moving average price of $367.24 and a two-hundred day moving average price of $375.80. The firm has a market cap of $148.59 billion, a P/E ratio of 50.17, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter in the previous year, the firm posted $2.50 earnings per share. The company's revenue was up 11.9% compared to the same quarter last year. On average, sell-side analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker's dividend payout ratio (DPR) is 45.41%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.